Advances in Cardiovascular Research. Volume 1. (Record no. 59490)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 11264nam a22005293i 4500 |
001 - CONTROL NUMBER | |
control field | EBC3018177 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | MiAaPQ |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20240729124054.0 |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
fixed length control field | m o d | |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr cnu|||||||| |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 240724s2010 xx o ||||0 eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9781612092133 |
Qualifying information | (electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
Canceled/invalid ISBN | 9781607417200 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (MiAaPQ)EBC3018177 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (Au-PeEL)EBL3018177 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (CaPaEBR)ebr10659099 |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (OCoLC)923657492 |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | MiAaPQ |
Language of cataloging | eng |
Description conventions | rda |
-- | pn |
Transcribing agency | MiAaPQ |
Modifying agency | MiAaPQ |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
Classification number | RC667 -- .A35 2010eb |
082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
Classification number | 362.196/10072 |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Schmitt, Lukas. |
245 10 - TITLE STATEMENT | |
Title | Advances in Cardiovascular Research. Volume 1. |
250 ## - EDITION STATEMENT | |
Edition statement | 1st ed. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Place of production, publication, distribution, manufacture | Hauppauge : |
Name of producer, publisher, distributor, manufacturer | Nova Science Publishers, Incorporated, |
Date of production, publication, distribution, manufacture, or copyright notice | 2010. |
264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | ©2010. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 1 online resource (480 pages) |
336 ## - CONTENT TYPE | |
Content type term | text |
Content type code | txt |
Source | rdacontent |
337 ## - MEDIA TYPE | |
Media type term | computer |
Media type code | c |
Source | rdamedia |
338 ## - CARRIER TYPE | |
Carrier type term | online resource |
Carrier type code | cr |
Source | rdacarrier |
490 1# - SERIES STATEMENT | |
Series statement | Advances in Cardiovascular Research ; |
Volume/sequential designation | v.1 |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Intro -- ADVANCES IN CARDIOVASCULAR RESEARCH, VOLUME 1 -- ADVANCES IN CARDIOVASCULAR RESEARCH, VOLUME 1 -- Contents -- Preface -- Chapter I The Mitral Valve: Development, Structure, Pathology & -- Tissue Engineering -- Abstract -- I. Development of the Mitral Valve Apparatus -- II. Histological Anatomy of the Mitral Valve -- III. Surface Topographical and Ultrastructural Anatomy of the Mitral Valve -- III.I. Surface Topography of the Mitral Valve -- III.II. Ultrastructure of the Mitral Valve -- III.II.I. Endocardial endothelium (EE) -- III.II.II. Valvar interstitial cells (VIC) -- III.II.III. Extracellular matrix (ECM) -- III.II.IV. Neural elements -- IV. Myxomatous Mitral Valve Disease (Canine Model) -- IV.I. Clinical Features and Natural Disease Progression -- IV.II. Pathology of Myxomatous Mitral Valve Disease -- IV.III. Pathogenesis and Pathophysiology of Myxomatous Mitral Valve Disease -- V. Mitral Valve Regeneration & -- Tissue Engineering -- V.I. Cell Sourcing for Mitral Valve Tissue Engineering -- V.II. Scaffold Development for Mitral Valve Tissue Engineering -- V.III. Bioreactor Development for Mitral Valve Tissue Engineering -- V.IV. Challenges in the Field of Mitral Valve Tissue Engineering -- References -- Chapter II Review of Treatment of Ventricular Fibrillation -- Abstract -- Cardiopulmonary Resuscitation -- Drug Therapy of Ventricular Fibrillation -- Introduction -- Amiodarone -- Sotalol -- Non anti-arrhythmic drugs that reduce risk of SCD -- Angiotensin Converting Enzyme (ACE) Inhibitors -- Aldosterone antagonists -- Statins -- Fish Oils -- Beta blockers -- Use of β blockers post myocardial infarction -- Use of β blockers in heart failure -- CIBIS I -- CIBIS II -- MERIT HF -- US Carvedilol Heart Failure Study -- COPERNICUS -- COMET (& -- BEST) Trial -- Automated External Defibrillators &. |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Public Access Defibrillation -- Introduction -- The Modern AED -- Public Access Defibrillation (PAD) -- Forms of PAD -- Site Specific -- Airline studies -- Airport studies -- Casino studies -- Community Based -- Public Access Defibrillation Trial -- Hybrid approaches -- Recent CPR vs CPR & -- AED Meta-analysis -- Cost effectiveness of public access defibrillation in public places -- Home Programmes -- Early AED at Home trials -- Home AED Trial (HAT) -- Summary of public access defibrillation -- The Implantable Cardioverter-Defibrillator -- Introduction -- Primary Prevention -- MADIT I -- MUSTT -- MADIT II -- DINAMIT -- CABG-PATCH -- DEFINITE -- ScD-HeFT -- META-ANALYSIS -- Summary -- Secondary Prevention -- Introduction -- Early and DUTCH Trials -- CASH -- CIDS -- AVID -- META-ANALYSIS -- Summary -- Cost effectiveness of ICDs -- Summing up and Future Directions -- VF ABLATION -- Abbreviations -- References -- Chapter III A Historical View of Advances in the Resuscitation of Patients in Ventricular Fibrillation from the Perspective of Emergency Medical Services -- Abstract -- Introduction -- A Brief History of the Development of Modern Day Cardiopulmonary Resuscitation and Defibrillation -- Cardiovascular Disease and Sudden Cardiac Death: The Demographics and Survival Rates of Patient in VF -- Mechanism of Sudden Cardiac Death and Ventricular Fibrillation: The Arrhythmogenicity of Myocardial Ischaemia -- The Management of Out-of-Hospital Cardiac Arrest: Evolution of Emergency Medical Services -- The Evolution of Advanced Life Support -- Establishment of the International Liason Committee on Resuscitation to Develop a Concerted International Approach -- The 2005 ILCOR Guidelines for Resuscitation: CPR before Defirbillation in VF Cardiac Arrest -- Conclusion: A Look to the Future -- References. |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Chapter IV The Ambiguous Role of Epinephrine in Ventricular Fibrillation -- Abstract -- Introduction -- Epinephrine in CPR -- Epinephrine in the Human Organism -- Adrenergic Receptor Classification -- Epinephrine's Actions -- Pathophysiology of CA -- Reperfusion Injury & -- Post-Resuscitation Myocardial Dysfunction -- Three-Phase Ventricular Fibrillation Model -- Adverse Effects of Epinephrine -- Coronary Vasoconstriction -- Increase in Myocardial Oxygen Consumption -- Increased Ventricular Ectopic Activity -- Pulmonary Ventilation Perfusion Defects -- Increase in Defibrillation Energy Requirements -- Platelet Aggregation -- Catecholamine Oxidation -- Mast Cell Degranulation -- Increase of the Severity of Post-Resuscitation Myocardial Dysfunction -- Factors Influencing Epinephrine's Effectiveness -- Epinephrine's Activity in VF Setting -- Receptor Desensitization -- CPR Quality -- Time to Drug Administration -- Epinephrine's Dose -- Epinephrine in CPR Research -- Epinephrine vs Placebo -- Alternative Pharmacologic Agents -- Vasopressin -- Vasopressin vs Epinephrine in Animal Studies -- Vasopressin vs Epinephrine in Clinical Studies -- Vasopressin Combined with Epinephrine vs Epinephrine Alone -- Adrenergic Agents -- Selective α 2-adrenoreceptor Agonists -- α-Methylnorepinephrine (α -ΜΝΕ) -- Norepinephrine -- Epinephrine and β-Blockers -- Epinephrine Combined with Vasopressin and Nitroglycerin -- Epinephrine Combined with Cariporide -- Epinephrine Combined with Levosimendan -- Causes of Discrepancies between Laboratory and Clinical Trials in CPR -- Laboratory CPR and Manual CPR -- Time and Route of Epinephrine Administration -- Subjects' Health Status -- End Points in CPR Trials -- Conclusion -- References -- Chapter V Defibrillation: Mechanisms, Waveforms, Energy Levels, Transthoracic Impedance and Automated External Defibrillators. |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Abstract -- Definition and Mechanisms -- Waveforms and Energy Levels -- One Versus 3 Shock Protocol -- Transthoracic Impedance and Optimal Defibrillation -- Electrode Position -- Automated External Defibrillators -- Conclusion -- References -- Chapter VI Acute Kidney Injury after Coronary Artery Bypass -- Abstract -- Introduction -- Incidence and Prognosis of Acute Kidney Injuries after Bypass Surgery -- Risk Factors Associated with Acute Kidney Injury -- A. The Patient -- B. Surgical Procedure -- C. CPB -- D. Post-Operative Period -- Mechanisms Leading to Acute Kidney Injury -- A. Specificity of Renal Vascularisation -- B. Hemodynamic Effects and Microcirculatory Disruption -- C. Systemic Inflammation and Ischemia-Reperfusion -- D. Embolism -- E. Toxicity -- Diagnosis of Acute Kidney Injury after Coronary Artery Bypass -- How Can We Prevent Acute Kidney Injury after Coronary Artery Bypass? -- A. General Measures -- B. Pharmacological Interventions -- C. Management of CPB -- Conclusion -- References -- Chapter VII Rheumatic Valvulopathy: Current Understanding of Pathogenesis and Perspective of Immunobiological Treatments -- Abstract -- Introduction -- Epidemiology and Etiologic Agent -- Genetic Susceptibility and Pathogenesis -- Diagnosis and Clinical Manifestations -- Carditis -- Arthritis -- Erythema Marginatum -- Subcutaneous Nodules -- Chorea -- Other Manifestations -- Laboratory Investigation -- Evidence of a Recent Streptococcal Infection -- Inflammatory Markers -- Synovial Fluid Analysis -- Differential Diagnosis -- Treatment -- Treatment of the Clinical Manifestations -- Surgical Treatment -- Vaccine -- Future Perspectives -- References -- Chapter VIII Microstructure of the Aortic Valve: Implications for Valvular Mechanics and Function -- Abstract -- Introduction -- Fibrosa -- Ventricularis -- Spongiosa -- Endothelium. |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Future Directions -- Determining the Effect of the Hydrated Nature of the Spongiosa on Leaflet Mechanical Behavior in Tension and Compression -- Characterizing the Composition, Density, and Location of Interconnecting Fibers in the Spongiosa -- Determining the Effect of the Layered Structure on Diffusion through the Aortic Valve -- Determining the Effect of the Layered Structure on VIC Phenotype and Function -- Determining the Influence of GAGs and PGs on Matrix Organization and Mechanical Properties -- Conclusion -- References -- Chapter IX Morphological Aspects in Analysis of Postoperative Remodeling of Left Ventricle in Patients with Icmp -- Abstract -- Introduction -- Materials and Methods -- Results and Discussion -- Conclusion -- References -- Chapter X Functional and Ischemic Mitral Regurgitation -- Abstract -- Introduction -- Ischemic Mitral Regurgitation -- Etiology and Epidemiology -- Pathophysiology and Diagnostic Assessment -- Experimental IMR -- Inferior and anterior infarction -- Annular dilatation -- Left ventricular dyssynchrony -- Dynamic IMR -- Echocardiographic measurements -- Surgical Technique -- Annuloplasty -- Procedures on the mitral leaflets -- Posterior mitral valve restoration -- Anterior leaflet augmentation -- Posterior leaflet extension -- Edge-to-edge -- Procedures on the subvalvular apparatus and papillary muscles -- Chordal cutting -- Papillary muscle sling -- Posterior papillary muscle relocation -- Ring plus String suture -- Procedures at the ventricular level -- Papillary muscle approximation - imbrication -- Left ventricular infarct transversal plication -- Left ventricular infarct longitudinal plication -- Coapsys and CorCap devices -- Minimally invasive and transcatheter procedures -- Current Attitudes and Indications for Surgery -- Conclusion -- References. |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Chapter XI Confounding of Genetic and Environmental Factors in Pregnancy-Induced Hypertension. |
588 ## - SOURCE OF DESCRIPTION NOTE | |
Source of description note | Description based on publisher supplied metadata and other sources. |
590 ## - LOCAL NOTE (RLIN) | |
Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cardiovascular system -- Diseases. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Internal medicine. |
655 #4 - INDEX TERM--GENRE/FORM | |
Genre/form data or focus term | Electronic books. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Konig, Timm. |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Relationship information | Print version: |
Main entry heading | Schmitt, Lukas |
Title | Advances in Cardiovascular Research. Volume 1 |
Place, publisher, and date of publication | Hauppauge : Nova Science Publishers, Incorporated,c2010 |
International Standard Book Number | 9781607417200 |
797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | Advances in Cardiovascular Research |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018177">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3018177</a> |
Public note | Click to View |
No items available.